Organisation
Intellectual Property
Administrative Office
Projects
1 - 10 of 16
- ATP13A2 agonists for Parkinson’s disease therapyFrom1 Mar 2024 → TodayFunding: IOF - technology validation in lab
- PHGDH-ASM: Phosphoglycerate dehydrogenase (PHGDH) activators as novel antiseizure medications (ASM) with dual mode of actionFrom1 Oct 2022 → TodayFunding: IOF - technology validation in lab
- VirusBank platform (state-of-the-art research platform for increased preparedness against viral epidemics and pandemics)From1 Jan 2022 → TodayFunding: Ministery of Economical Affairs
- Targeting transcription factor addiction in acute leukemia (TaTFAL)From1 Oct 2021 → TodayFunding: FWO Strategic Basic Research (SBO)
- Understanding the anti-cancer effects of new YAP/TAZ inhibitors to treat malignant mesotheliomaFrom1 Mar 2021 → TodayFunding: Foundations, funds and other with scientific goal
- MATATUM: Validation and druggability development of macrophage-specific targets in the tumor microenvironment.From1 Jan 2018 → 31 Dec 2021Funding: FWO Strategic Basic Research (SBO)
- Targeting ZEB pathways to tackle aggressive (colorectal) cancer (ZENTACC).From1 Jan 2018 → 31 Dec 2021Funding: FWO Strategic Basic Research (SBO)
- Towards a combined post-exposure prophylaxis and successful treatment of rabies in humansFrom1 Oct 2017 → 30 Sep 2020Funding: FWO research project (including WEAVE projects)
- Valorization of novel strategies for the prevention of viral infection and inhibition of viral replication.From1 Nov 2015 → TodayFunding: IOF - Industrial Research Fund, IOF - mandates
- iKap: Targeting nucleocytoplasmic transport for novel anti-cancer therapy.From1 Oct 2015 → 30 Nov 2019Funding: SBO (Strategic basic research)
Publications
1 - 10 of 44
- Identification of fungicidal 2,6-disubstituted quinolines with Candida antibiofilm activity(2012)
Authors: Nicolas Delattin, Dorothée Bardiot, Arnaud Marchand, Patrick Chaltin, Katrijn De Brucker, Bruno Cammue, Karin Thevissen
Pages: 12243 - 12251 - Structure based discovery and optimization of first-in-class inhibitors of the HIV-1 IN-LEDGF/p75 interaction(2011)
Authors: Arnout Voet, Frauke Christ, Arnaud Marchand, Patrick Chaltin, Stefan Nicolet, Sergei Strelkov, Zeger Debyser, Marc De Maeyer
Pages: 120 - 121 - Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication(2010)
Authors: Frauke Christ, Arnout Voet, Belete Ayele Desimmie, Sergei Strelkov, Marc De Maeyer, Patrick Chaltin, Zeger Debyser
Pages: 442 - 448 - An allosteric binding site of the alpha 7 nicotinic acetylcholine receptor revealed in a humanized acetylcholine-binding protein(2018)
Authors: Fabian Gruss, Sam Noppen, Steve Peigneur, Patrick Chaltin, Sandra Liekens, Jan Tytgat, Chris Ulens
Pages: 2534 - 2545 - Identification of Fungicidal 2,6-Disubstituted Quinolines with Activity against Candida Biofilms(2012)
Authors: Patrick Chaltin, Bruno Cammue, Karin Thevissen
Pages: 12243 - 12251 - Identification of drugs that restore primary cilium expression in cancer cells(2016)
Authors: Ali Talebi, Arnaud Marchand, Jonas Dehairs, Sebastian Munck, Patrick Chaltin, Johan Swinnen
Pages: 9975 - 92 - Antibacterial Activity of 1-[(2,4-Dichlorophenethyl)amino]-3-Phenoxypropan-2-ol against Antibiotic-Resistant Strains of Diverse Bacterial Pathogens, Biofilms and in Pre-clinical Infection Models(2017)
Authors: Valerie Defraine, Laure Verstraete, Arnaud Marchand, Patrick Chaltin, Maarten Fauvart, Jan Michiels
Pages: 2585 - 1-((2,4-Dichlorophenethyl)Amino)3-Phenoxypropan-2-ol Kills Pseudomonas aeruginosa through Extensive Membrane Damage(2018)
Authors: Valerie Defraine, Veerle Liebens, Toon Swings, Bram Weytjens, Kathleen Marchal, Arnaud Marchand, Patrick Chaltin, Maarten Fauvart, Jan Michiels
- Elucidation of the mode of action of a new antibacterial compound active against Staphylococcus aureus and Pseudomonas aeruginosa(2016)
Authors: Evelien Gerits, Eline Blommaert, Bram Weytjens, Dries De Maeyer, Kathleen Marchal, Arnaud Marchand, Patrick Chaltin, Pieter Spincemaille, Katrijn De Brucker, Karin Thevissen, et al.
- 2-(2-Oxo-morpholin-3-yl)-acetamide Derivatives as Broad-Spectrum Antifungal Agents(2015)
Authors: Karin Thevissen, Katrijn De Brucker, Annelies Peeters, Patrick Chaltin, Bruno Cammue, Arnaud Marchand
Pages: 1502 - 1512